Search

Your search keyword '"Cork, Michael J."' showing total 476 results

Search Constraints

Start Over You searched for: Author "Cork, Michael J." Remove constraint Author: "Cork, Michael J."
476 results on '"Cork, Michael J."'

Search Results

13. Diaper dermatitis prevalence and severity: Global perspective on the impact of caregiver behavior

14. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

15. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

21. Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial

23. Characterization of skin barrier defects using infrared spectroscopy in patients with atopic dermatitis.

27. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial

29. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials

31. Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial

34. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

37. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

39. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis

40. 337 Dupilumab treatment is not associated with an increased overall risk of infections in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis

42. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis

43. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

45. Emollients for prevention of atopic dermatitis: 5‐year findings from the BEEP randomized trial

47. A real‐world retrospective observational study exploring NHS resource use in England for the management of moderate‐to‐severe atopic dermatitis in secondary care for children and adolescents

48. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Catalog

Books, media, physical & digital resources